Laekna Licenses Cancer Drug Candidate to Vasque Bio Outside Greater China

MT Newswires Live06-10

Laekna (HKG:2105) granted Vasque Bio exclusive rights to develop and commercialize its cancer drug candidate LAE118 outside Greater China under a licensing agreement, according to a Wednesday Hong Kong bourse filing.

The biotechnology company will receive a $10 million upfront payment and is eligible for up to $517 million in development and sales milestone payments under the deal.

Laekna will also have the right to acquire, at no additional cost, up to a high-teen-percentage stake in Vasque Bio's outstanding common stock, or to receive cash payments in lieu of the shares.

In addition, the company is entitled to tiered royalties ranging from single-digit to double-digit percentages on future net sales of LAE118 in the licensed territory.

It may also receive additional payments tied to certain strategic transactions involving the drug candidate, the filing said.

Shares of Laekna were down over 4% in Wednesday morning trade.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2642414263?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-10 11:29","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2642414263","market":"sg","top_or_hot":-1,"title":"Laekna Licenses Cancer Drug Candidate to Vasque Bio Outside Greater China","media":"MT Newswires Live","content":"<html><body><p> Laekna (HKG:2105) granted Vasque Bio exclusive rights to develop and commercialize its cancer drug candidate LAE118 outside Greater China under a licensing agreement, according to a Wednesday Hong Kong bourse filing.</p><p>The biotechnology company will receive a $10 million upfront payment and is eligible for up to $517 million in development and sales milestone payments under the deal.</p><p>Laekna will also have the right to acquire, at no additional cost, up to a high-teen-percentage stake in Vasque Bio's outstanding common stock, or to receive cash payments in lieu of the shares.</p><p>In addition, the company is entitled to tiered royalties ranging from single-digit to double-digit percentages on future net sales of LAE118 in the licensed territory.</p><p>It may also receive additional payments tied to certain strategic transactions involving the drug candidate, the filing said.</p><p>Shares of Laekna were down over 4% in Wednesday morning trade.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Laekna Licenses Cancer Drug Candidate to Vasque Bio Outside Greater China</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLaekna Licenses Cancer Drug Candidate to Vasque Bio Outside Greater China\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-06-10 11:29</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Laekna (HKG:2105) granted Vasque Bio exclusive rights to develop and commercialize its cancer drug candidate LAE118 outside Greater China under a licensing agreement, according to a Wednesday Hong Kong bourse filing.</p><p>The biotechnology company will receive a $10 million upfront payment and is eligible for up to $517 million in development and sales milestone payments under the deal.</p><p>Laekna will also have the right to acquire, at no additional cost, up to a high-teen-percentage stake in Vasque Bio's outstanding common stock, or to receive cash payments in lieu of the shares.</p><p>In addition, the company is entitled to tiered royalties ranging from single-digit to double-digit percentages on future net sales of LAE118 in the licensed territory.</p><p>It may also receive additional payments tied to certain strategic transactions involving the drug candidate, the filing said.</p><p>Shares of Laekna were down over 4% in Wednesday morning trade.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1161","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2642414263","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2642414263","pubTimestamp":1781062147,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Laekna  granted Vasque Bio exclusive rights to develop and commercialize its cancer drug candidate LAE118 outside Greater China under a licensing agreement, according to a Wednesday Hong Kong bourse filing.The biotechnology company will receive a $10 million upfront payment and is eligible for up to $517 million in development and sales milestone payments under the deal.Laekna will also have the right to acquire, at no additional cost, up to a high-teen-percentage stake in Vasque Bio's outstanding common stock, or to receive cash payments in lieu of the shares.In addition, the company is entitled to tiered royalties ranging from single-digit to double-digit percentages on future net sales of LAE118 in the licensed territory.It may also receive additional payments tied to certain strategic transactions involving the drug candidate, the filing said.Shares of Laekna were down over 4% in Wednesday morning trade.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1161":"生物科技","02105":"来凯医药-B"},"translate_title":"Laekna向大中华区以外的Vasque Bio授予癌症候选药物许可","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02105":1},"content_text":"Laekna (HKG:2105) granted Vasque Bio exclusive rights to develop and commercialize its cancer drug candidate LAE118 outside Greater China under a licensing agreement, according to a Wednesday Hong Kong bourse filing.The biotechnology company will receive a $10 million upfront payment and is eligible for up to $517 million in development and sales milestone payments under the deal.Laekna will also have the right to acquire, at no additional cost, up to a high-teen-percentage stake in Vasque Bio's outstanding common stock, or to receive cash payments in lieu of the shares.In addition, the company is entitled to tiered royalties ranging from single-digit to double-digit percentages on future net sales of LAE118 in the licensed territory.It may also receive additional payments tied to certain strategic transactions involving the drug candidate, the filing said.Shares of Laekna were down over 4% in Wednesday morning trade.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2642414263","isCrawlerRequest":true}